Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Multiple Myeloma
Interventions
DRUG

plerixafor

Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4\*10\^6 CD34+ cells/kg body weight had been collected.

Trial Locations (2)

10021

Memorial Sloan-Kettering Cancer Center, New York

19107

Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AnorMED

INDUSTRY

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00396383 - Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation | Biotech Hunter | Biotech Hunter